2026-01-06 - Analysis Report
Here's a comprehensive analysis of Merck & Co. Inc. (MRK) based on the provided data.

**1. Return Rate Comparison**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of healthcare products.
*   **MRK Cumulative Return:** 22.93%
*   **S&P 500 (VOO) Cumulative Return:** 91.00%
*   **Divergence:** -68.1
    *   The divergence between MRK and the S&P 500 is significant.  MRK has substantially underperformed the broader market over the analyzed period.
    *   **Relative Divergence:** 23.8. This means the current divergence is relatively close to the minimum divergence experienced in the past, suggesting it's near the lower end of its historical performance range compared to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 24.0% | 14.7% | 21.0% | 0.7 | 183.8 |
| 2017-2019  | 37.0% | 14.7% | 20.0% | 0.7 | 218.8 |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7 | 196.8 |
| 2019-2021  | 0.0% | 19.3% | -43.0% | 0.6 | 193.2 |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5 | 279.7 |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3 | 274.8 |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3 | 250.8 |
| 2023-2025  | -24.0% | 39.0% | -86.0% | 0.3 | 265.4 |

*   **CAGR:** The Compound Annual Growth Rate has fluctuated significantly over the periods, showing periods of strong growth (2017-2019) and recent periods of decline (2022-2025, 2023-2025).
*   **MDD:** Maximum Drawdown shows the largest peak-to-trough decline during the period.  The MDD has increased, indicating greater volatility and risk in recent years.
*   **Alpha:** Alpha measures the stock's performance relative to the benchmark (likely the S&P 500).  Negative Alpha values indicate underperformance.  Recent periods (2018-2020, 2019-2021, 2022-2024, 2023-2025) have seen particularly weak Alpha, suggesting MRK has struggled to generate returns independently of market movements.
*   **Beta:** Beta measures the stock's volatility relative to the market.  A Beta of around 0.3-0.7 suggests MRK is less volatile than the overall market.
*   **Cap(B):**  Represents market capitalization in billions. The capitalization has been rising and is in the range of 183.8-279.7.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 106.45
*   **Last-market:** {'price': 107.44, 'previousClose': 106.45, 'change': 0.93}
*   **5-day SMA:** 106.23
*   **20-day SMA:** 102.01
*   **60-day SMA:** 94.48

*   **Analysis:**  The stock price is above all three moving averages, indicating a short-term, mid-term, and long-term upward trend.  The 5-day SMA is closest to the current price, while the 60-day SMA is the furthest, suggesting that the recent gains are significant. The recent movement of price is showing an increasing trend.

**3. RSI, PPO, Market Risk Indicator, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 75.58

    *   The RSI is above 70, indicating that the stock is currently in overbought territory, which could suggest a potential pullback in the near future.
*   **PPO:** 0.0841

    *   PPO measures the percentage difference between two moving averages. A positive PPO suggests that the shorter-term moving average is above the longer-term moving average, indicating an upward trend.
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (8 shares - Safe - MRI:0.80) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2026-01-02)

    *   This indicates a buy signal but with only 90% of cash.
*   **Recent (20 days) relative divergence change:** 2.0 (+): 단기상승

    *   This confirms the recent upward price movement and suggests that MRK's performance relative to the S&P 500 has improved slightly in the short term.
*   **Price Change:** {'price': 107.44, 'previousClose': 106.45, 'change': 0.93}

    *   The `change` value of 0.93 indicates a significant day-to-day price change, reflecting market volatility and potential factors driving MRK's price (such as news events).
*   **Expected Return (%):** -27.3

    *   This is a concerning figure, suggesting that long-term investment in MRK from this point might significantly underperform the S&P 500 based on the model's calculations.

**4. Recent News & Significant Events**

*   **Bullish Signals:**
    *   Morgan Stanley raised MRK's price target.
    *   MRK stock hit a 52-week high.
    *   Analysts are discussing the company's potential for success.
*   **Important Dates:**
    *   Cidara deal deadline mentioned.
*   **Overall:** The news is predominantly positive, focusing on price target increases, new highs, and analyst optimism. This positive sentiment could be contributing to the recent price increase.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean 1.90)
*   **Target Price:** Average target of $110.04, with a high of $139 and a low of $83.

    *   The consensus "Buy" rating and the average target price slightly above the current price ($107.44) suggest that analysts generally believe the stock has more room to grow.
    *   Target price dispersion (High: $139, Low: $83) is relatively wide, suggesting some uncertainty about the stock's future performance.
*   **Recent Rating Changes:** No changes are displayed here.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-11-05 | 2.32 | 17.28 B$   |
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2025-11-05 | 1.25 | 16.66 B$   |

*   **Trend:** Recent EPS and revenue figures are generally trending upward, especially when comparing the most recent quarter to previous ones. The latest EPS and Revenue figures show substantial growth.
*   **Inconsistency:** There's a duplicate entry for 2025-11-05, which needs clarification.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.28B    | 77.69%        |
| 2025-06-30   | $15.81B    | 77.50%        |
| 2025-03-31   | $15.53B    | 77.98%        |
| 2024-12-31   | $15.62B    | 75.50%        |
| 2024-09-30   | $16.66B    | 75.51%        |

*   **Revenue Trend:** Revenue has generally increased over the past five quarters, indicating strong sales performance.
*   **Profit Margin:** Consistently high, indicating good operational efficiency.

**Capital and Profitability**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-09-30   | $51.85B    | 11.16%  |
| 2025-06-30   | $48.99B    | 9.04%   |
| 2025-03-31   | $48.34B    | 10.51%  |
| 2024-12-31   | $46.31B    | 8.08%   |
| 2024-09-30   | $44.50B    | 7.09%   |

*   **Equity Trend:** Equity has been consistently increasing, suggesting good financial health and reinvestment of profits.
*   **ROE Trend:** Return on Equity (ROE) has been increasing, indicating that the company is becoming more efficient at generating profits from its equity.

**7. Comprehensive Analysis**

*   **Underperformance vs. S&P 500:** MRK has significantly underperformed the S&P 500 over the longer term, which is a major concern.
*   **Recent Positive Momentum:**  Recent news, analyst ratings, and short-term price action are positive, suggesting a potential turnaround.
*   **Strong Financials:** Revenue, profit margins, equity, and ROE are all trending in the right direction, indicating a fundamentally healthy company.
*   **Concerning Expected Return:** The negative expected return is a major red flag and warrants further investigation. This could be due to factors not captured in the analysis, or it could be a valid warning signal.
*   **Overbought Condition:** The RSI suggests the stock may be overbought in the short term.
*   **Mixed Signals:**  The analysis presents a mixed picture.  While the company has strong financials and recent positive momentum, the long-term underperformance, negative expected return, and overbought RSI warrant caution.

**Recommendation:**

*   **Due to the significantly negative expected return and long-term underperformance relative to the S&P 500, a *cautious* approach is recommended.**
*   Consider the overbought condition (high RSI) and the possibility of a pullback.
*   Given the positive recent news and analyst ratings, a small, carefully managed position *could* be considered, but only after further due diligence and risk assessment.
*   Pay close attention to future earnings reports and news events to gauge the sustainability of the recent positive momentum.

**Further Investigation:**

*   **Understand the drivers of the negative expected return.** What assumptions are being used in the model to generate this result?
*   **Investigate the reasons for MRK's long-term underperformance.** Are there specific challenges the company is facing, or are there industry-wide factors at play?
*   **Analyze the company's pipeline of new products and potential blockbusters.** The pharmaceutical industry is driven by innovation, and the company's future success depends on its ability to develop and commercialize new drugs.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.